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Abstract
The array of specialized neuronal and glial cell types that characterize the adult central nervous system originates from
neuroepithelial proliferating precursor cells. The transition from proliferating neuroepithelial precursor cells to neuronal lineages is
accompanied by rapid global changes in gene expression in coordination with epigenetic modiﬁcations at the level of the chromatin
structure. A number of genetic studies have begun to reveal how epigenetic deregulation results in neurodevelopmental disorders
such as mental retardation, autism, Rubinstein–Taybi syndrome and Rett syndrome. In this review we focus on the role of the methyl-
CpG binding protein 2 (MeCP2) during development of the central nervous system and its involvement in Rett syndrome. First, we
present recent ﬁndings that indicate a previously unconsidered role of glial cells in the development of Rett syndrome. Next, we
discuss evidence of how MeCP2 deﬁciency or loss of function results in aberrant gene expression leading to Rett syndrome. We also
discuss MeCP2’s function as a repressor and activator of gene expression and the role of its different target genes, including
microRNAs, during neuronal development. Finally, we address different signaling pathways that regulate MeCP2 expression at both
the post-transcriptional and post-translational level, and discuss how mutations in MeCP2 may result in lack of responsiveness to
environmental signals.
Introduction
Understanding the molecular mechanisms that control the phenotypic
identity of distinct neuronal classes at deﬁned regions within the
central nervous system constitutes a widely relevant issue in
developmental neuroscience. Neurons permanently exit the cell
cycle and remain quiescent. Neuronal mitotic quiescence is crucial
for the maintenance of the complexly wired brain. Therefore,
neuronal differentiation encompasses an elaborate developmental
program in which neurogenic and antiproliferative signals work in
concert to ensure the differentiated state (Perez-Martinez & Jaworski,
2005).
During development, mitotically active precursors located within
the neuroepithelium give rise to all the neuronal and glial cells of the
brain. Recent genetic studies in vertebrate and invertebrate models
have shown that neuronal differentiation is under the control of
complex regulatory networks of transcription factors, which are
activated in response to inductive signals. The coordinated actions of
these proteins direct neuronal fate identity in appropriate spatial and
temporal contexts during central nervous system development (Jurata
et al., 2000; Lee & Pfaff, 2001; Fig. 1).
Environmental cues, via speciﬁc intracellular signaling pathways,
control neuronal differentiation at multiple levels: neuronal precursor
cell cycle control, migration, synaptogenesis, neuronal survival and
neurotransmitter phenotype. As mentioned above, these cellular
responses result from the induction of timely coordinated cascades of
gene expression controlled by speciﬁc and ubiquitous transcription
factors. These transcription factors in turn induce either the expression
of structural genes required for speciﬁc functions of a given neuronal
lineage and⁄or the expression of non-coding RNAs that play an
important regulatory role. Among the small non-coding RNAs
identiﬁed so far are those with (i) gene-silencing effects [small
interfering RNAs (siRNAs) and microRNAs (miRNAs)] at the post-
transcriptional level and (ii) small modulatory double-strand RNAs
(smRNAs) that regulate gene expression at the transcriptional level
through double-stranded RNA⁄protein interactions (Mattick &
Makunin, 2005). In mammals, certain miRNAs have been implicated
as important regulators in the maintenance of the pluripotent cell state
during early development (Houbaviy et al., 2003) and neurogenesis
(Sempere et al., 2004). However, recent studies have demonstrated that
the action of transcription factors mediating neuronal differentiation
depends on speciﬁc epigenetic traits like histone post-translational
modiﬁcations, polyADP-ribosylation and DNA methylation. Here, we
review the latest studies aimed at understanding how an epigenetic
deregulation results in neurodevelopmental disorders. Speciﬁcally, we
focus on the role of the methyl-CpG binding protein 2 (MeCP2) in
neuronal development and disease. We also discuss different MeCP2
targets including miRNAs, and mechanisms of MeCP2 regulation.
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Developmental stages in mammals are established by genetic and
epigenetic programs. Epigenetic information is normally deﬁned as
those processes that are inherited through mitosis or meiosis
inﬂuencing gene expression independently of the DNA sequence.
They constitute signals that are interpreted to regulate gene expression
and cellular differentiation, among other cellular processes. The
chromatin structure provides an additional level of regulation over
gene expression as chromatin can switch between a closed or
transcriptionally repressive state, to an open or transcriptionally
permissive state (Berger, 2007). These changes in chromatin archi-
tecture are regulated by different processes including chromatin
remodelers (Clapier & Cairns, 2009), histone variants (Kamakaka &
Biggins, 2005), histone post-translational modiﬁcations (Kouzarides,
2007) and DNA methylation (Miranda & Jones, 2007). DNA
methylation is a covalent modiﬁcation that, in the case of vertebrates,
consists of the addition of a methyl group to the 5¢ carbon of cytosine
residues (Turek-Plewa & Jagodzinski, 2005). Cytosine methylation
normally occurs in the context of the palindromic 5¢-CG-3¢ (CpG)
dinucleotide (Holliday & Pugh, 1975; Bird, 1978). In mammals,
between 60 and 90% of all CpGs are methylated (Bird, 1986). In
vertebrates, there are CpG-rich regions referred to as CpG islands,
which are predominantly located in regulatory regions. These islands
can be found in approximately 60% of all mammalian genes
(Antequera & Bird, 1993), and are mostly found in an unmethylated
state (Bird, 1986). DNA methylation patterns vary signiﬁcantly
throughout development. Cytosine methylation is established and
maintained by DNA methyltransferases (Dnmts), whose expression is
tightly regulated during development (reviewed in Goll & Bestor,
2005). In mammals, de-novo methylation is carried by two enzyme
families: Dnmt3a and Dnmt3b (Okano et al., 1999). Both proteins are
essential for normal development as Dnmt3a knock-out mice become
runted after birth and die at around 4 weeks of age; Dnmt3b knock-out
shows embryonic defects and causes death before embryonic day 15.5.
Homozygous animals, mutant for both Dnmt3a and Dnmt3b, exhibit a
more severe phenotype than individual mutants; they die before
embryonic day 11.5, suggesting an overlapping function for these
proteins in embryogenesis (Okano et al., 1999).
Following replication, when the newly synthesized DNA strand is
unmethylated, an enzyme binds to hemimethylated sites and catalyzes
the transfer of a methyl group on the daughter strand to restore the
palindromic methyl CpG conﬁguration (Leonhardt et al., 1992). This
maintenance methylation activity is catalyzed by Dnmt1 and ensures
that the established methylation patterns are preserved over many cell
generations, and provides a means for heritable transcriptional control
during development. Dnmt1 is expressed throughout embryonic
development; in the adult stage Dnmt1 exists as two isoforms, Dnmt1
and Dnmt1b (Bonﬁls et al., 2000).
DNA methylation has been shown to play an important role in
several processes, including the suppression of tissue-speciﬁc genes
and imprinted genes, X chromosome inactivation, and stability of
transposable elements (Jaenisch et al., 1985; Keshet et al., 1986;
Becker et al., 1987; Li et al., 1993; Panning & Jaenisch, 1996; Walsh
et al., 1998). It has also been shown that methylation confers
additional stability to the genome by providing a more tightly packed
chromatin, in particular along repetitive sequences and constitutive
heterochromatic regions to avoid unspeciﬁc recombination events
(Colot et al., 1996; Chen et al., 1998; Hashimshony et al., 2003). The
most common effect of DNA methylation is gene silencing, which can
be achieved in two ways: (i) a transcription factor binding site can be
altered by the presence of a methylated cytosine, preventing its
recognition and binding by the transcription factor; and (ii) DNA
methylation can recruit methyl-CpG binding proteins that, in turn, are
capable of recruiting chromatin-remodeling factors (reviewed in Klose
& Bird, 2006).
Fig. 1. Neuronal differentiation results from speciﬁc gene expression regulation. (A) In neural stem cells (NSCs), sex determining region Y-box 2 (Sox2) is highly
expressed and represses the transcription of neuronal genes like Neurogenic differentiation 1 (NeuroD1). As cells differentiate from NSCs to neural progenitor cells,
Sox2 expression is lost and NeuroD1 is activated by wingless-type MMTV integration site family member (Wnt) signaling-dependent binding of T-cell factor/
lymphoid enhancer factor (TCF ⁄ LEF) to its promoter (Kuwabara et al., 2009). (B) In proliferating neural cells, Sox2 and Oct4 (also known as POU5F1 for POU
class 5 homeobox 1) are highly expressed and together regulate a wide variety of genes, including Sox2 itself. Sox2 and Oct4 bind to an enhancer region (named
SRR2) located downstream of Sox2 gene, which is found in an unmethylated state. Sox2 and Oct4 occupancy also correlate with open chromatin marks (H3Ac)i n
the enhancer region and throughout the gene. As cells differentiate into neurons, Sox2 and Oct4 occupancy on the SRR2 enhancer is lost, the CpGs in the enhancer
become methylated and the open chromatin marks (H3Ac) are lost (Chew et al., 2005).
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tion factors from binding to their recognition sequences (Watt &
Molloy, 1988). For example, the glial ﬁbrillary acidic protein gene is
activated during astrocyte differentiation by the demethylation of a
CpG dinucleotide located in a signal transducer and activator of
transcription 3 binding element (STAT3) (Takizawa et al., 2001).
Although methylation normally leads to transcriptional silencing,
methylation of repressor protein-binding elements, as in the imprinted
insulin-like growth factor 2 (Igf2) gene, can increase its expression
(Eden et al., 2001; Murrell et al., 2001).
Methylation signals can be interpreted directly by methyl-CpG-
binding proteins that can alter gene transcription (Klose & Bird, 2006).
In vertebrates, there are two families of methyl-CpG-binding proteins:
the methyl-binding domain (MBD) family and the Kaiso family
(reviewed in Bogdanovic & Veenstra, 2009). Five members of the
MBD family have been identiﬁed: MeCP2, MBD1, MBD2, MBD3
and MBD4, although MBD3 presents a mutation on the MBD domain
and is unable to bind methylated CpGs (Hendrich & Bird, 1998).
Unlike the MBD members, the Kaiso family lacks an MBD, but binds
to methyl-CpGs through a zinc ﬁnger domain (Prokhortchouk et al.,
2001). All members of the MBD family, except MBD4, have been
shown to act as transcriptional repressors in vitro (Hendrich & Bird,
1998). In contrast, MBD4 has been associated with minimizing
mutations at 5-methylcytosine and in DNA repair (Bellacosa et al.,
1999; Hendrich et al., 1999).
A number of studies have shown that members of the MBD family
play different roles throughout development and in disease. This is
attributed to the capability of the MBD proteins to interact with
repressing complexes such as Nucleosome Remodeling and histone
Deacetylation (NuRD), RE1-silencing transcription factor (REST) and
REST corepressor 1 (CoREST), as well as with various chromatin
remodelers such as histone deacetylases (HDACs), Dnmt1, Polycomb,
Brahma and Alpha thalassemia/mental retardation syndrome X-linked
(ATRX) (Jones et al., 1998; Nan et al., 1998, 2007; Zhang et al.,
1999; Lunyak et al., 2002; Fuks et al., 2003; Kimura & Shiota, 2003;
Harikrishnan et al., 2005). The interaction of MBDs with HDAC
complexes (Prokhortchouk et al., 2001) contributes to condensing the
chromatin into higher order structures that are transcriptionally silent
(Ng et al., 1999; Wade et al., 1999; Zhang et al., 1999; Feng &
Zhang, 2001). Therefore, the MBDs provide a link between DNA
methylation-mediated transcriptional repression, histone deacetylation
and chromatin remodeling. Among the different histone post-transla-
tional modiﬁcations, acetylation on different residues of histone 3 and
histone 4 as well as methylation on histone 3 lysine 4 (H3K4me) are
normally associated with an open chromatin state, whereas histone 3
methylation on lysine 9 and lysine 27 (H3K9me and H3K27me) is
associated with a closed chromatin state (Kouzarides, 2007). There are
some cases in which DNA methylation has been associated with
histone marks (Vaissiere et al., 2008). For example, reduction of
cytosine methylation leads to an increase of histone 3 acetylation on
lysine 9 and lysine 14 (H3K9Ac and H3K14Ac), whereas H3K4
methylation (H3K4me) causes a decrease in H3K9me in mammals
(Nguyen et al., 2001; Bachman et al., 2003). However, it is still
unknown whether a functional relationship exists between DNA
methylation and histone methylation to control gene expression.
Methyl-CpG binding protein 2 and disease
Methyl-CpG binding protein 2 was one of the ﬁrst members of the
MBD family to be discovered (Lewis et al., 1992). Apart from the
MBD domain, MeCP2 has a transcriptional repressor domain that is
able to interact with other co-repressors (like deacetylase complexes),
two nuclear localization signals and a tryptophan-tryptophan domain
in the C-terminus that facilitates binding to nucleosomal DNA and is
thought to mediate protein–protein interactions (reviewed in Bienvenu
& Chelly, 2006; Fig. 3).
Methyl-CpG binding protein 2 is required for correct brain function
and development. Loss of MeCP2 has been shown to delay neuronal
maturation and synaptogenesis, and cause Rett syndrome (RTT;
reviewed in Matijevic et al., 2009). RTT is an X-linked, neurodevel-
opmental disorder that is characterized by a normal period of
development from 6 to 18 months, followed by a subsequent loss of
acquired speech and motor skills. Patients with RTT can also develop
mental retardation, stereotyped hand movements, ataxia, seizures,
microcephaly, autism and respiratory dysfunctions (Hagberg et al.,
1983). RTT is mostly caused by mutations on the MeCP2 gene
(Fig. 2), but mutations for cyclin-dependent kinase-like 5 (CDKL5)
have also been associated with RTT (reviewed in Matijevic et al.,
2009; both genes are located on the X chromosome). Although
CDKL5 has been shown to be able to phosphorylate MeCP2 and cause
its release from the DNA (Mari et al., 2005; Bertani et al., 2006), a
direct functional relationship between these two molecules in RTT is
controversial (see below).
Methyl-CpG binding protein 2 brain levels in newborn mice are
very low but increase signiﬁcantly with development, reaching a
maximum at 5 weeks, after which MeCP2 expression remains
constant (Skene et al., 2010). RTT has mostly been attributed to
gene deregulation caused by a lack of MeCP2 expression in adult
neurons (Luikenhuis et al., 2004). This correlates with the fact that
patients with RTT develop normally through the ﬁrst 6–18 months of
age after which they start presenting the characteristics of the disease
(Hagberg et al., 1983). This idea is supported by the phenotype of the
MeCP2-null mice. MeCP2-null mice develop normally until 5–
6 weeks of age, when they begin to show neurological symptoms,
hind limb clasping and irregular breathing. They also present a
reduction in weight and neuronal cell size, and normally die between 6
and 12 weeks (Chen et al., 2001; Guy et al., 2001).
Even though RTT has normally been attributed to neuronal MeCP2
deﬁciency (Luikenhuis et al., 2004), several studies have begun to
implicate non-neural cells in the development of the disease (Maezawa
& Jin, 2010; Ballas et al., 2009; Maezawa et al., 2009; Table 1).
Recently, it has been shown that MeCP2 is not only expressed in
neurons, as previously thought (Skene et al., 2010), but is also
expressed in embryonic and adult stages in all glial cell types,
including astrocytes, oligodendrocyte progenitor cells, oligodendro-
cytes and microglia. Analysis of the RTT mouse brain (Ballas et al.,
2009) shows loss of MeCP2 expression in astrocytes as well as low
H3K9me3 levels, whereas H3Ac is enriched. Co-culture of neurons
and astrocytes demonstrates that RTT astrocytes are unable to support
normal dendritic morphology in wild-type (WT) hippocampal neu-
rons, which show fewer and shorter dendrites. Culturing WT
hippocampal neurons in astrocytic conditioned media from RTT
astrocyte cultures results in aberrant dendritic morphology and a
reduced neuronal density, whereas RTT neurons cultured in WT
astrocytic conditioned media show normal dendritic morphology,
suggesting that MeCP2 regulates the expression of soluble factors that
are required for neuronal survival.
Another study has demonstrated that astrocytes from MeCP2
+ ⁄ )
mice show only 30% of the MeCP2 protein level with respect to WT,
whereas MeCP2
+ ⁄ ) neurons show 70–80% compared with WT
(Maezawa et al., 2009). Astrocytic levels of MeCP2 do not
correspond with the expected values for X chromosome inactivation,
suggestive of a non-cell-autonomous mechanism of MeCP2 expres-
sion in astrocytes. In agreement with this, MeCP2 expression was
MeCP2 target genes and Rett syndrome 1565
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co-cultured with MeCP2
+ ⁄ ) astrocytes; additionally, astrocyte MeCP2
protein levels in MeCP2
+ ⁄ ) mice show a signiﬁcant reduction with
age. Inhibition of the gap junction communication resulted in a
reduced spread of the MeCP2 deﬁciency and also rescued part of the
phenotype. A more recent study by the same group showed that
microglia also play an important role in the development of RTT
(Maezawa & Jin, 2010). WT hippocampal neurons cultivated in
conditioned media from very pure microglia cultures from MeCP2-
null mice had shorter and thinner dendrites, with stunted arborization,
whereas those grown in WT microglia conditioned media showed a
normal phenotype. Consistently, neurons grown in MeCP2-null
microglia conditioned media showed a reduced staining for MAP2
(Microtubule-associated protein 2, a dendritic marker), acetylated
tubulin (reduction indicates microtubule disruption), PSD95 (post-
synaptic density-95, a post-synaptic marker) and glutamate receptor
interacting protein 1 (a scaffold protein in the post-synaptic compart-
ment). All of this suggests that MeCP2-null microglia conditioned
media damages post-synaptic elements of excitatory synapses
(Maezawa & Jin, 2010). MeCP2-null microglia did not present an
activated morphology or enhanced proliferation, indicative that the
neurotoxic effect is not dependent on microglia activation. The authors
report that this neurotoxic effect results from an excess of glutamate
release from the MeCP2-null microglia and that it is released through
channels of the gap junction. As in Maezawa et al. (2009), blocking
the gap junction channels reduced the levels of released glutamate and
rescued neuron morphology. Contrary to previous results (Ballas
et al., 2009), neurons grown in astrocytic conditioned media, from
both WT and MeCP2-null mice, did not display damage in dendrites
or synapses. For the effects seen in astrocytes, Maezawa & Jin (2010)
suggest a loss of function in MeCP2-null astrocytes, which would be
unable to support adequate dendritic development, whereas Ballas
et al. (2009) suggest a gain of function in which astrocytes secrete a
neurotoxic factor into the medium. Still further analysis would be
necessary to determine the variability of soluble factors that are
secreted by both astrocytes and microglia caused by an MeCP2
deﬁciency. Given that MeCP2 can regulate gene expression both
positively and negatively (Chahrour et al., 2008; Ben-Shachar et al.,
2009; Urdinguio et al., 2010) (see below), it is probable that loss of
MeCP2 could lead to the overexpression of neurotoxic factors as well
a reduction in soluble factors that are necessary for neuronal survival.
Overall, these results point out a previously unconsidered important
role of glial cells in the development of the RTT.
Methyl-CpG binding protein 2 targets genes in the central
nervous system
Searching for possible MeCP2 targets to explain the RTT phenotype
has not been an easy task. Until recently only two genes were
Fig. 2. MeCP2 protein structure and common mutations associated with RTT. The MeCP2 protein domains, the most frequent mutations found in RTTand different
phosphorylation sites are depicted. MeCP2 has different domains including a methyl CpG binding domain (MBD), a transcriptional repression domain (TRD), two
nuclear localization signals (NLS) and a WW domain in the C-terminus. The black arrows (top) indicate the position of the eight most common mutations found in
RTT; note that they locate preferentially to the MBD and TRD domains (Matijevic et al., 2009). Known phosphorylation sites of MeCP2 are shown (bottom) for
CaMKII (S421) and homeodomain-interacting kinase 2 (S80; Zhou et al., 2006; Bracaglia et al., 2009), as well as predicted phosphorylation sites for cyclin
dependent kinase 5 (CDK5), PKCa ⁄ b, AKT, PKCe and PKCd.
Table 1. MeCP2 deﬁciency in different cells
Cell type Effect Reference(s)
Neurons Abnormal dendritic and axon
development
Larimore et al. (2009)
Astrocytes Unable to sustain proper neuron
development
Ballas et al. (2009)
Maezawa et al. (2009)
Microglia Neurotoxic effect by excessive
glutamate release
Maezawa & Jin (2010)
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derived neurotrophic factor (Bdnf) and distal-les homeobox 5 (dlx5),
which is on an imprinted region in chromosome 7 (reviewed in
Chadwick & Wade, 2007). MeCP2 regulates Bdnf expression by
binding to the promoter IV and repressing its transcription. This
repression can be relieved by neuronal depolarization, which triggers
Ca
2+-dependent phosphorylation of MeCP2 and subsequent dissoci-
ation of MeCP2 from the Bdnf promoter IV, leading to increased Bdnf
transcription (Chen et al., 2003; Zhou et al., 2006). However, contrary
to what was expected, patients with RTT as well as mouse models of
RTTshow lower levels of Bdnf compared with healthy individuals and
WT animals, respectively (Chang et al., 2006). Many studies have
been performed to elucidate how MeCP2 regulates Bdnf expression
(Chen et al., 2003; Wang et al., 2006; Zhou et al., 2006), which is key
to understanding RTTas most of the RTT phenotypes can be attributed
to a deregulation of Bdnf expression in the brain (Chang et al., 2006;
Table 2). Accordingly, Bdnf overexpression rescues the morphology
of MeCP2-deﬁcient neurons (Larimore et al., 2009). Another study
suggests that Bdnf downregulation in MeCP2-deﬁcient mice may be
mediated by repressor and co-repressor molecules like REST and
CoREST (Abuhatzira et al., 2007). MeCP2 is able to repress both
REST and CoREST, which correlate with an overexpression of these
two factors in MeCP2-deﬁcient brain. REST and CoREST can bind
between Bdnf promoters I and II, and repress Bdnf transcription. Thus,
in the absence of MeCP2, Bdnf transcription is mainly regulated by
REST⁄CoREST, which do not respond to neuronal activity, resulting
in lower levels of Bdnf. In WT mice, MeCP2 binds to promoter IVof
Bdnf and mediates neuronal activity-dependent transcription of Bdnf.
Deregulation of REST⁄CoREST could also help to explain the
expression pattern of other genes that have been found to be
downregulated in MeCP2-deﬁcient brains (Nomura et al., 2008).
In addition to its well-accepted role as a transcriptional repressor, a
considerable amount of data suggests a role for MeCP2 as a
transcriptional activator (Chahrour et al., 2008; Ben-Shachar et al.,
2009; Urdinguio et al., 2010). Given that some of the phenotypes
associated with RTT could be attributed to hypothalamic dysfunction,
Chahrour et al. (2008) deﬁned the hypothalamic gene proﬁle of WT,
MeCP2-null and MeCP2-overexpressing (MeCP2-tg) mice using
microarray screening. This study identiﬁed 2582 genes that were
misregulated in both MeCP2-tg and MeCP2-null mice. The authors
identiﬁed 2148 genes that were upregulated in the MeCP2-tg mice and
downregulated in the null mice, and only 377 that were downregulated
in MeCP2-tg mice and upregulated in null mice. Among these genes
are different neurotransmitters (e.g. corticotropin-releasing hormone
and somatostatin) and neurotransmitter receptors (e.g. thyroid hor-
mone receptor alpha and thyrotropin-releasing hormone receptor) that
could help to explain the hypothalamic dysfunction. Also of note are
different genes coding for regulatory proteins like Bdnf, reelin, cAMP
responsibe element binding protein 1 (Creb1) and Creb3, as well as
chromatin remodelers like different HDACs and transformation/
transcription domain-associated protein (Trapp), the latter being
previously identiﬁed as an enriched transcript in the hypothalamus
(Guerra-Crespo et al., 2011; Table 3). Most of these genes were found
to be upregulated by MeCP2, whereas only reelin and HDAC9 were
found to be repressed by MeCP2. This shows that in the hypothalamus
the majority of genes targeted by MeCP2 are positively regulated,
which clashes with the idea of MeCP2 being primarily a repressor.
However, bisulﬁte sequencing showed that genes repressed by MeCP2
presented a higher degree of methylation than genes activated by
MeCP2. The fact that MeCP2 binds preferentially to methylated DNA
(Skene et al., 2010) suggests that, to promote gene expression,
MeCP2 could be acting through another protein to bind and to activate
Table 2. Regulation of Bdnf by MeCP2
Mechanism Model Reference(s)
In the absence of neural activity, MeCP2 binds to Bdnf promoter IV and
represses Bdnf expression
Membrane depolarization causes calcium-dependent MeCP2 phosphorylation
and subsequent release from Bdnf promoter IV
Rat hippocampal neurons Chen et al. (2003)
Zhou et al. (2006)
Loss of MeCP2 affects Bdnf secretion Adult MeCP2-null mice (MeCP2
) ⁄ y) Wang et al. (2006)
Receptor of activated protein kinase C1 (Rack1) is able to dissociate MeCP2
from Bdnf promoter IV, leading to Bdnf activation
SH-SY5Y human neuroblastoma cells He et al. (2010)
MeCP2-deﬁcient brain presents lower levels of Bdnf MeCP2-deﬁcient human and mouse brains Abuhatzira et al. (2007)
MeCP2 deﬁciency increases the expression of both REST and CoREST, which
in turn downregulate Bdnf levels by binding between Bdnf promoters I and II
MeCP2-deﬁcient human and mouse brains Abuhatzira et al. (2007))
Table 3. MeCP2 targets and their function
Targets Function Reference(s)
Bdnf Essential for neuronal survival, differentiation, synaptic plasticity and dendrite outgrowth See Table 2
Dlx5 Imprinted gene, homeobox transcription factor, regulates the enzymes that synthesize GABA Horike et al. (2005)
miR-137 Role in differentiation and proliferation, inhibits Ezh2 Szulwach et al. (2010)
miR-184 Role in differentiation and proliferation Nomura et al. (2008)
Liu et al. (2010)
REST Repression of neurogenic genes Abuhatzira et al. (2007)
In the hypothalamus Chromatin remodelers – HDACs and Trapp
Neurotransmitters – Crh and Ssh
Receptors – Trhr and Thra
Chahrour et al. (2008)
Crh, corticotropin-releasing hormone; Dlx5, distal-les homeobox 5; Ssh, somatostatin; Trhr, thyrotropin-releasing hormone receptor; Thra, thyroid hormone receptor
alpha; Trapp, transformation ⁄ transcription domain-associated protein.
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cipitation assays show that MeCP2 is complexed with CREB1 in the
promoter region of genes activated by MePC2, whereas a repressed
gene did not show CREB1 enrichment. Interestingly, expressing both
MeCP2 and CREB1, but not MeCP2 alone, enhances transcription of
the MeCP2 target genes showing functional synergy. Thus, the effect
of MeCP2 on gene expression depends on the proteins present at the
promoter region of MePC2 target genes; when MeCP2 binds to co-
repressors and HDACs it results in transcriptional repression.
Nevertheless, a more thorough study of the methylation state in the
genes activated by MeCP2 will help to shed more light on this issue,
as well as looking for co-activators interacting directly with MeCP2
other than CREB1.
A similar study performed in the cerebellum identiﬁed 1180 and
1102 altered genes in the MeCP2-tg and MeCP2-null mice, respec-
tively (Ben-Shachar et al., 2009). The fold change in most cases was
subtle, between 1.2- and 2-fold, with the exception of the gene Prl2c2
(prolactin-like protein), which was overexpressed 12-fold in the
MeCP2-tg mice with respect to WT mice. This gene was not reported
in the previous hypothalamus screening (Chahrour et al., 2008). As in
the hypothalamus, MeCP2 activated the majority of the altered genes
in the cerebellum. These results further support the idea that MeCP2
may act as a positive regulator of gene expression in the central
nervous system and that this function is not restricted to the
hypothalamus. Interestingly, whereas in the hypothalamus the screen
found thousands of genes that were differentially expressed in the
MeCP2-Tg and MeCP2-null mice (Chahrour et al., 2008), in the
cerebellum only hundreds of misregulated genes were identiﬁed
(Ben-Shachar et al., 2009). This difference indicates that, although
some of the targets in different brain regions might be the same, there
is still a considerable amount of genes that are differentially affected
between different regions of the brain and suggests speciﬁc mecha-
nisms of gene regulation that depend on the neuronal phenotype. This
also supports the importance of epigenetic regulation and the greater
impact it has on determining speciﬁcity for each tissue and cell type
during development. It is also possible that MeCP2 might act
preferentially as an activator on some cell types, whereas on others it
might act as a repressor. Thus, looking at speciﬁc regions of the brain
can provide more insights about MeCP2 targets and their regulation.
However, it remains to be determined whether all of these genes are
direct targets of MeCP2 or are regulated indirectly.
Methyl-CpG binding protein 2 and microRNAs
Recently, the role of miRNAs in a number of pathologies has started to
be elucidated. To decipher the impact of miRNAs downstream of
MeCP2, Urdinguio et al. (2010) used a speciﬁc miRNA microarray to
determine the expression proﬁle in the MeCP2-null mice compared
with WT mice. Sixty-ﬁve miRNAs showed differential expression
between the two conditions. Among these, 45 were downregulated in
MeCP2-null mice, whereas 18 were upregulated. Bisulﬁte sequencing
and chromatin immunoprecipitation assays showed that, among four
of the miRNAs identiﬁed, MeCP2 binds to methylated CpGs present
on the 5¢ regulatory region of three of them. MeCP2 binds to the
methylated 5¢ region of microRNA-29b (miR-29b), which is upreg-
ulated in MeCP2-null mice, correlating with the role of MeCP2 as a
repressor for miR-29b. However, both miR-146a and miR-146b were
downregulated in the MeCP2-null mice and had MeCP2 enrichment at
their methylated 5¢ ends, supporting a role for MeCP2 as a
transcriptional activator. Both of these miRNAs target IRAK1
(interleukin-1 receptor-associated kinase; Taganov et al., 2006), which
is upregulated in RTT mouse models. Therefore, downregulation of
miR-146a and miR-146b could lead to higher levels of IRAK1. Thus,
enhanced interleukin-1b signaling in glia cells resulting from elevated
IRAK levels might contribute to the release of neurotoxic agents
(Thornton et al., 2006) leading to neuronal death as previously
described (Ballas et al., 2009; Maezawa et al., 2009; Maezawa & Jin,
2010).
The miRNAs prove a very interesting method of regulation as they
can act at both the post-transcriptional level and the translational level
(Filipowicz et al., 2008). This suggests that the subtle changes in the
mRNA levels of potential MeCP2 targets observed in different studies
may not reﬂect the protein level. Thus, a proteomic approach in these
models could certainly provide valuable information to fully under-
stand RTT.
Other studies have also focused on the regulation of miRNAs by
MeCP2. One of these miRNAs is miR-184, which is found on an
imprinted region of chromosome 9 (Nomura et al., 2008). Its
expression is restricted to brain and testis and the paternal allele is
the only one that is expressed in the brain. A CpG-rich region located
downstream of the miR-184 transcript has been identiﬁed as
hypermethylated only in brain (Nomura et al., 2008). KCl treatment
increases miR-184 expression similarly to Bdnf in cortical neurons.
Chromatin immunoprecipitation assays have shown that after KCl
treatment the enrichment of MeCP2 in the miR-184 CpG-rich region
was reduced in the paternal allele only, correlating with miR-184
speciﬁc paternal expression. The MeCP2-deﬁcient brain showed
reduced miR-184 levels, which suggest a regulation similar to Bdnf.
Interestingly, MBD1 also binds to this locus in the brain but, contrary
to MeCP2, MBD1 deﬁciency causes miR-184 overexpression, as
would be expected after the loss of a repressor (Liu et al., 2010).
These observations point out the distinct mechanisms used by the
different members of the MBD family to regulate gene expression in
the brain.
Furthermore, miR-184 results in an interesting MeCP2 target as it
has been shown that this miRNA plays a role during neural
development by inducing proliferation and inhibiting both neuronal
and astrocytic differentiation (Liu et al., 2010). miR-184 targets
Numblike, which has been shown to increase neuronal differentiation.
These results suggest that MeCP2 might also regulate neuronal
differentiation by indirectly targeting Numblike through miR-184.
Interestingly, miR-184 is expressed in the two known brain regions
(hippocampus and subventricular zone) of adult neurogenesis in vivo.
However, it remains to be determined whether adult neurogenesis is
altered in the MePC2-deﬁcient mice.
Another miRNA that is regulated by MeCP2 is miR-137 (Szulwach
et al., 2010). Overexpression of miR-137 enhances proliferation,
whereas inhibition leads to a decreased proliferating capacity. Adult
neural stem cell (aNSC) differentiation correlates with increased levels
of miR-137. Consequently, MeCP2 deﬁciency promotes premature
miR-137 expression before aNSC differentiation, consistent with
MeCP2’s role as a repressor (Matijevic et al., 2009). Chromatin
immunoprecipitation assays using MeCP2 antibodies show enrich-
ment in the 5¢-region of miR-137 relative to the null mice (MeCP2
) ⁄ y)
that correlates with increased methylated CpGs (Szulwach et al.,
2010). Analysis of different chromatin marks in MeCP2
) ⁄ y mice
showed an increase in H3K4me3 and H3K9Ac in the region
surrounding the miR-137 gene compared with WT mice (Szulwach
et al., 2010); both histone marks are associated with an open
chromatin state. During aNSC differentiation the levels of H3K4Me
and H3K9Ac are increased, supporting MeCP2 deﬁciency leading to
the premature establishment of an open chromatin conﬁguration.
Additionally, an enrichment of Sox2 in the upstream region of miR-
137 was observed, which is lost in the MeCP2-null mice, suggesting
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Accordingly, immunoprecipitation assays demonstrated Sox2–MeCP2
protein–protein interactions (Szulwach et al., 2010).
The enhancer of Zeste homolog 2 (Ezh2), a H3K27 methyltrans-
ferase, has been reported as a putative target for miR-137 (Szulwach
et al., 2010). Ezh2 overexpression reduces cell proliferation and co-
expression with miR-137 increases the number of differentiated
neurons. Overexpression of miR-137 reduces Ezh2 protein levels; the
same was observed in MeCP2-null mice where miR-137 is overex-
pressed. This effect is speciﬁc as reducing miR-137 recovered normal
Ezh2 in MeCP2
) ⁄ y mice (Szulwach et al., 2010). Thus, the
overexpression of miR-137 and the decrease in Ezh2 correlated with
an overall reduction of H3K27me3 in mouse aNSCs (Fig. 3 and
Table 2). These results point out a cross-talk between different
epigenetic processes to regulate gene expression leading to correct
neural development and differentiation. Once again, it would be
interesting to determine whether adult neurogenesis is altered in
patients with RTT.
Methyl-binding domains and cell differentiation
In addition to the necessary role of MeCP2 in mature neuronal and
glial cells, it also has an important role during cell differentiation.
MeCP2 promotes neuronal differentiation of neural stem cells while
repressing astrocytic differentiation [induced by astrogenic factors like
Leukemia inhibitory factor (Lif) and Bone morphogenetic protein 2
(BMP2); Tsujimura et al., 2009]. Interestingly, the truncated mutant of
MeCP2 (R168X, lacking the complete transcriptional repressor
domain), identiﬁed in patients with RTT (Amir et al., 1999), is
unable to promote and suppress neuronal and astrocytic differentia-
tion, respectively. This suggests a necessary role of this domain for the
correct regulation by MeCP2.
In addition to MeCP2, other MBDs have also been implicated
during cell differentiation processes (Li et al., 2008; MacDonald
et al., 2010). The ﬁbroblast growth factor 2 (FGF-2) is crucial for
maintaining aNSCs in an undifferentiated state (Palmer et al., 1995;
Zheng et al., 2004). Consequently, FGF-2 overexpression results in a
signiﬁcant reduction of neuronal differentiation. FGF-2 expression is
regulated negatively by MBD1 that binds to a speciﬁc CpG-rich
region on the mouse and rat FGF-2 promoters (Li et al., 2008).
Accordingly, Mbd1
) ⁄ ) mice show increased levels of FGF-2 that
correlate with impaired aNSC differentiation and adult neurogenesis.
Depletion of Mbd1 using RNA interference results in a neuronal
differentiation percentage that is signiﬁcantly reduced from aNSCs.
These results corroborate the crucial role of MBD1 in neuronal
differentiation.
In the adult olfactory epithelium, the olfactory receptor neurons
(ORNs) are in continuous replacement (Murdoch & Roskams, 2007).
Mbd2 has two alternative splice variants: MBD2a and MBD2b
(Hendrich & Bird, 1998). MBD2a is found predominantly in the
mature ORNs, whereas MBD2b is found in progenitors and
immature post-mitotic neurons. Consistently, the Mbd2-null mice
exhibit an increase in progenitor cell proliferation and a reduced
number of mature ORNs (MacDonald et al., 2010). In contrast,
MeCP2 expression increases ORN maturation. MeCP2-null mice
show an increased number of immature ORNs with no signiﬁcant
change in the number of progenitors or mature ORNs. Speciﬁc
Dnmts and HDACs are present in the different stages of ORN
differentiation (MacDonald et al., 2005). Cycling progenitor cells
express high levels of Dnmt3b and HDAC1, whereas they are
downregulated in post-mitotic neurons, which express Dnmt3a and
HDAC2. As neurons mature, Dnmt3a and HDAC2 expression levels
are downregulated, whereas HDAC1 is expressed again. Therefore,
in addition to MeCP2, MBD2 could regulate pivotal stages of ORN
development via interaction with Dnmts, HDACs and MeCP2 as
they are co-expressed at different stages of ORN maturation and
have been reported to co-immunoprecipitate (MacDonald et al.,
2005, 2010).
Fig. 3. MeCP2 regulates differentiation through miR-137 and Ezh2. MeCP2 binds to methylated CpGs in a region upstream of miR-137 and, together with Sox2,
represses miR-137 transcription. Ezh2, a target of miR-137, is not repressed and is able to establish H3K27me3 marks. This process enhances differentiation and
inhibits proliferation of aNSCs. The absence of MeCP2 correlates with a gain of open chromatin marks (H3K9Ac and H3K4me3) in the area surrounding miR-137
and a loss of Sox2 in the regulatory region. Ezh2 is repressed by miR-137 that leads to a global loss of H3K27me3 marks; this enhances proliferation and inhibits
differentiation of aNSCs (Szulwach et al., 2010).
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existence of speciﬁc interactions between Dnmts and histone methyl-
transferases that incorporate repressive histone marks. Dnmt3 together
with the H3K9 methyltranferase G9A cooperatively ensures proper
neurogenesis in zebraﬁsh (Rai et al., 2010). Whether the Dnmt3
family in mammals displays a similar Dnmt–histone methyltransferase
relationship will be a matter for future investigations.
Signals controlling methyl-CpG binding protein 2 gene
expression and function
A precise regulation of MeCP2 levels is needed as both deﬁcient and
overexpressing brains exhibit RTT-like phenotypes (Ramocki et al.,
2009). Quantiﬁcation studies have estimated 16 · 10
6 molecules of
MeCP2 per nucleus in neurons (Skene et al., 2010). The estimated
number of methylated CpG sites is about 40 · 10
6 sites per nucleus,
meaning that there are enough MeCP2 molecules to bind approxi-
mately half of the CpG sites. Histone H1 is present at a ratio of one
molecule per nucleosome, although in neurons this relationship is
reduced to one H1 molecule for every two nucleosomes (Pearson
et al., 1984). MeCP2 can compete with H1 for binding to methylated
chromatin, functioning as a linker histone (Nan et al., 1997). In
agreement with this, MeCP2-null mouse brain shows a twofold
increase in H1, supporting the idea that, in the brain, MeCP2 binds
half of the nucleosomes and H1 binds the other half (Skene et al.,
2010). This suggests that MeCP2 deﬁciency could also lead to an
overall chromatin decondensation that would result in gene deregu-
lation as seen in previous screens.
The MeCP2 gene is known to have multiple polyadenylation sites
(Reichwald et al., 2000); the longer transcript (approximately 10 kb)
is predominantly transcribed in the brain and its 3¢ untranslated region
contains target motifs for different miRNAs. One of these sites is for
miR-132, which plays a role in neurite outgrowth mediated by Bdnf
(Vo et al., 2005). Overexpression of miR-132, as well as treatment
with Forskolin and KCl (which induce miR-132 expression through
CREB), in primary cortical neurons decreased MeCP2 protein levels
(Klein et al., 2007). Bdnf levels are increased both by MeCP2
overexpression and by blocking miR-132 with an antisense oligo-
nucleotide. MeCP2 overexpression induces Bdnf expression, which in
turn increases miR-132 transcription that downregulates MeCP2
protein production. This suggests a homeostatic mechanism for
maintaining correct MeCP2 levels (Klein et al., 2007); however, little
is known about additional factors regulating the expression of MeCP2
gene in the brain.
Few reports are available regarding extracellular signals regulating
MeCP2 function. Recently, it has been shown that MeCP2 is
phosphorylated by Calcium/calmodulin-dependent protein kinase II
(CaMKII) on Ser421 in response to neuronal depolarization and Bdnf
(Zhou et al., 2006). This phosphorylation releases MeCP2 from the
promoter IV of Bdnf resulting in increased Bdnf expression (Chen
et al., 2003). Consistent with this, expression of an MeCP2 S421A
mutant prevents neurite arborization and reduces Bdnf expression (Tao
et al., 2009), indicating that MeCP2 phosphorylation at this residue
promotes MeCP2 release from its targets allowing their expression.
Although MeCP2 is expressed in many adult tissues it is phosphory-
lated at Ser421 almost exclusively in the adult brain (Zhou et al.,
2006), suggesting that phosphorylation of MeCP2 at this residue is
required for homeostatic brain functions. MeCP2 phosphorylation at
the amino-terminus also modulates its DNA binding and silencing
activity. In contrast to Ser421, phosphorylation at Ser80 is required for
MeCP2 binding to DNA and correct regulation of target genes like
gene trap locus 2 (Gtl2) and proopiomelanocortin (Pomc) among
others (Tao et al., 2009). Transgenic knock-in mice carrying the S80A
mutation show reduced MeCP2 binding to target genes and
consequently aberrant gene expression (Tao et al., 2009). The
homeodomain-interacting kinase 2 has been shown to phosphorylate
MeCP2 at Ser80 (Bracaglia et al., 2009). Accordingly, both the
homeodomain-interacting kinase 2-deﬁcient mice and S80A knock-in
mice show locomotion defects, suggesting that phosphorylation at this
residue by HIP2K regulates MeCP2 activity in vivo (Zhang et al.,
2007). Interestingly, although signals that promote neuronal survival
like neuronal activity and calcium ﬂuxes lead to Ser80 dephosphor-
ylation and Ser421 phosphorylation, MeCP2 phosphorylation by
HIP2K at Ser80 has been associated with cell death (Bracaglia et al.,
2009). Thus, it remains to be determined whether phosphorylation at
this site promotes or represses the expression of pro-apoptotic or
antiapoptotic genes, respectively; and also whether the phenotypes
observed in the S80A knock-in mice and homeodomain-interacting
kinase 2-deﬁcient mice result from altered neural cell death. Never-
theless, it seems that both Ser80 dephosphorylation and Ser421
phosphorylation are required to dissociate MeCP2 from DNA in
response to neuronal activity and calcium inﬂux.
As mentioned above, mutations in CDKL5 have been identiﬁed in
patients with RTT and other encephalopathies (Matijevic et al., 2009).
The fact that MeCP2–CDKL5 protein–protein interactions have been
shown by two independent groups, and that mutations in CDKL5
found in patients with RTT alter its kinase activity and cellular
distribution (Mari et al., 2005), suggest that these naturally occurring
mutations alter the MeCP2–CDKL5 interaction and point out a
functional role for these molecules in RTT development. Although it is
not yet clear whether MeCP2 is a direct target of CDKL5, Chen et al.
(2010) have shown that CDKL5 is required for normal neurite
outgrowth, a process that is altered in RTT neurons (Jellinger et al.,
1988). Interestingly, Bdnf regulates neurite outgrowth by promoting
CDKL5 kinase activity leading to ras-related C3 botulinum toxin
substrate 1 (rac-1) activation and neurite arborization (Chen et al.,
2010). Thus, we propose that, during normal development, neuronal
activity and other extracellular signals promote MeCP2 dephosphor-
ylation at Ser80 and phosphorylation at Ser421 alleviating MeCP2
repression of the Bdnf gene. Bdnf is then produced, secreted and
through its receptor initiates an autocrine loop that further inhibits
MeCP2 function at two levels: (i) preventing MeCP2 DNA binding
through phosphorylation mediated by CDKL5 and⁄or CAMKII and
(ii) reducing MeCP2 levels by inducing miR-132 via CREB, thus
ensuring the expression of Bdnf and other genes involved in neurite
outhgrowth (Fig. 4).
Brain-derived neurotrophic factor, through its speciﬁc receptor
Neurotrophic tyrosine kinase receptor type 2 (TrkB), activates distinct
signal transduction pathways [protein kinase C (PKC), v-akt murine
thymoma viral oncogene homolog 1 (AKT) and mitogen-activated
protein kinase (MAPK)] that regulate neural functions (Yoshii &
Constantine-Paton, 2010). MeCP2 protein contains different domains
that may be targeted by these pathways as demonstrated by a
bioinformatic analysis (Motif Scan) performed in our laboratory. This
analysis revealed potential phosphorylation sites for cyclin-dependent
kinase 5 (CDK5) in the central region of the molecule (Ser164,
Ser178, Ser341, Ser350 and Ser360), as well as putative sites for
different members of the PKC family – at the amino-terminus for
PKCa⁄b (Ser113) and in the central region for PKCe and PKCd
(Ser292; Fig. 3). Interestingly, a potential AKT phosphorylation site
(Ser357) is located within a putative MeCP2–14.3.3 interaction
domain (SPKGRSSS
357ASSPPKK). This domain also contains
Ser350 and Ser360, which could be phosphorylated by CDKL5
(Fig. 2). 14.3.3 proteins regulate protein function by steric competition
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The interaction of 14.3.3 proteins with their molecular targets is
regulated by phosphorylation events (Deribe et al., 2010). Both AKT-
and PKC-mediated phosphorylation of BCL2-associated agonist of
cell death (Bad) or v-raf-1 murine leukemia viral oncogene homolog 1
(Raf), among other targets, regulates cell survival and proliferation,
respectively. Moreover, cyclin-dependent kinases regulate the cell
cycle in part by phosphorylating 14.3.3 partners (Morrison, 2009).
Taken together, it is possible that Bdnf prevents MeCP2 transcriptional
functions by promoting its interaction with 14.3.3 proteins through a
mechanism involving MeCP2 phosphorylation on Ser357 by AKT
and⁄or on Ser350 and Ser360 by CDKL5, thus favoring neurite
outgrowth (Fig. 4).
Several of the mutations observed in MeCP2 associated with RTT
are located near putative phosphorylation sites – mutation of the
Arg110 residue could alter the phosphorylation of Ser113 by PKCa⁄b,
mutation of Arg294 might affect phosphorylation of Ser292 by PKCe
or PKCd, and mutations of Arg168 could impair Ser164 phosphor-
ylation by CDKL5 (Fig. 4). This strongly suggests that mutations in
MeCP2 found in RTT could impair Bdnf-mediated MeCP2 regulation
resulting in abnormal neurite outgrowth. However, it remains to be
determined whether MeCP2 is phosphorylated by any of these kinases
in response to Bdnf and whether this modulates MeCP2-dependent
gene expression.
Conclusions
Epigenetic regulation of chromatin architecture plays an essential role
in brain development and synaptic plasticity, particularly in brain areas
related to cognitive and emotional processes. Although the gross
anatomy of the brain is largely established at birth, cognitive
development during the post-natal period depends upon reorganization
in synaptic connectivity driven by sensory experience (Wiesel, 1982).
Several neurodevelopmental cognition disorders manifest during this
period, suggesting that they might be primarily diseases of synaptic
maturation (Zoghbi, 2003). Most major mental illnesses have been
proposed to result from multiple risk genes, which supports a stressful
environment triggering epigenetic changes in the expression of normal
genes (Murgatroyd et al., 2009). Both inherited risk genes as well as
abnormalities in epigenetic regulation of normal genes have been
implicated in the pathophysiology of many neurodevelopmental or
psychiatric disorders. The examples discussed here highlight the
importance of methylomics, the regulation of gene expression by
methylating DNA and histones, as a key epigenetic mechanism in RTT.
Further mechanistic understanding of RTT depends on identifying
and validating additional genes responsible for this disorder, specially
focusing on the targets that MeCP2 might have on different brain cell
types and distinct neuronal phenotypes. Accordingly, a recent study
demonstrates that MeCP2 regulates L1 retrotransposition speciﬁcally
in neurons (Muotri et al., 2010). These observations provide a new
mechanism by which loss of MeCP2 might result in altered gene
expression leading to disease. However, additional studies are needed
to evaluate the effects of MeCP2 deﬁciency in glial cells as well as at
earlier stages of neuronal development, and not just focusing on
mature neurons. Also, determining the various levels of cross-talk
between different epigenetic mechanisms would help understand the
processes leading to RTT and other neurodevelopmental diseases. It
would be interesting to determine whether single nucleotide poly-
Fig. 4. Regulation of MeCP2 expression by Bdnf. Post-translational regulation of MeCP2 – MeCP2 is phosphorylated by CaMKII in response to neuron
depolarization and Bdnf signaling (Zhou et al., 2006). MeCP2 could also be phosphorylated by other kinases downstream of the Bdnf signaling pathway (dashed
lines) resulting in interactions with the 14.3.3 proteins, thus regulating MeCP2 localization and function. Post-transcriptional regulation of MeCP2 – MeCP2’s 3¢
untranslated region contains sites for miR-132, which is activated by CREB. CREB is also downstream of the Bdnf signaling pathway, suggesting the presence of a
regulatory loop between Bdnf and MeCP2. AKT, v-akt murine thymoma viral oncogene homolog 1; CAMKK, calcium ⁄ calmodulin-dependent protein kinase
kinase; DAG, diacylglycerol; ERK ⁄ MAPK, mitogen activated protein kinase; GAB1, GRB2 associated binder; GRB2, growth factor receptor bound protein 2; IP3,
inositol triphosphate; MEK ⁄ MAPKK, mitogen activated protein kinase kinase, PI3K, phosphoinositide-3-kinase; PKC, protein kinase C; PLCc, Phospholipase C
gamma 1; Ras, rat sarcoma viral oncogene homolog; RSK, ribosomal protein S6 kinase; SHC, Src homology 2 domain containing transforming protein 1; SOS, son
of sevenless.
MeCP2 target genes and Rett syndrome 1571
ª 2011 The Authors. European Journal of Neuroscience ª 2011 Federation of European Neuroscience Societies and Blackwell Publishing Ltd
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in the genes encoding for DNA methyl transferases, histone-
modifying enzymes or chromatin-remodeling complexes play a role
in the development of neurodevelopmental, neurodegenerative or
psychiatric disorders.
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